Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282102 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18747143 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL14898381 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL13282208 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL19289866 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL13282112 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL19738597 | 0.88 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18789586 | 0.88 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18426952 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL21128960 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTABCC4ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMAN-LA ROCHE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021188659-A1 | HELICAL STAPLED PEPTIDES AND USES THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11008366-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10253067-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-9957299-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9937126-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | HIF1A, HIF1AN, EGLN3 | ALDH1A1 2295/4885LMNA 2417/4885MAPT 4811/4885 |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | MCL1, BCL2L1, BCL2L11 | ALDH1A1 4380/4885LMNA 3573/4885MAPT 4088/4885 |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885LMNA 1629/4885MAPT 2576/4885 |
| US-10253067-B2 | Peptidomimetic macrocycles and uses thereof | TP53, TP53BP1, MDM2 | ALDH1A1 4043/4885LMNA 2157/4885MAPT 3347/4885 |
| US-10308699-B2 | Peptidomimetic macrocycles | GHRHR, GHSR, GHITM | ALDH1A1 4843/4885LMNA 3985/4885MAPT 3661/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | ALDH1A1 4313/4885LMNA 2447/4885MAPT 1449/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | ALDH1A1 4722/4885LMNA 4139/4885MAPT 4226/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | ALDH1A1 4716/4885LMNA 3294/4885MAPT 905/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | ALDH1A1 4459/4885LMNA 4476/4885MAPT 1935/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | ALDH1A1 4687/4885LMNA 3875/4885MAPT 4537/4885 |
| US-11008366-B2 | Peptidomimetic macrocycles | GLP1R, PROKR1, VIP | ALDH1A1 4756/4885LMNA 3419/4885MAPT 2413/4885 |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | ALDH1A1 4570/4885LMNA 2565/4885MAPT 1649/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | ALDH1A1 4789/4885LMNA 3298/4885MAPT 3687/4885 |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | WNT3A, CTNNBL1, WNT1 | ALDH1A1 4235/4885LMNA 1788/4885MAPT 4501/4885 |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | ALDH1A1 4722/4885LMNA 4139/4885MAPT 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.